Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc (NDRA) pioneers advanced medical imaging through its TAEUS technology and Nexus 128 system, offering non-invasive solutions for liver diagnostics and preclinical research. This page consolidates all official announcements and third-party analyses about the company’s technological advancements and strategic initiatives.
Access real-time updates on regulatory milestones, clinical trial progress, and partnerships driving innovation in photoacoustic imaging. Investors and researchers will find detailed coverage of product developments like the TAEUS liver fat quantification system and Nexus 128’s 4D scanning capabilities.
Key updates include financial results, intellectual property filings, and collaborations with global research institutions. All content is verified for accuracy and relevance to ensure informed decision-making about this emerging leader in cost-effective diagnostic imaging.
Bookmark this page to stay informed about NDRA’s progress in addressing unmet needs in NAFLD/NASH diagnosis and expanding applications of thermo-acoustic ultrasound technology across healthcare markets.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, at 2:00 p.m. Eastern Time. Management will also hold virtual one-on-one meetings with investors throughout the day. ENDRA is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers cost-effective tissue visualization comparable to MRI, initially targeting liver fat measurement for assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). For further details, visit www.endrainc.com.
ENDRA Life Sciences (NASDAQ:NDRA) will participate in two virtual investment conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, where a recorded presentation will be available on demand starting September 13. The second is the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 20-23, with a live presentation on September 21 at 1:15pm ET. ENDRA specializes in Thermo Acoustic Enhanced UltraSound (TAEUS), a technology aimed at visualizing tissue at a fraction of MRI costs, initially focusing on liver health diagnostics.
ENDRA Life Sciences (NASDAQ:NDRA) reported its second-quarter 2021 results, highlighting significant operational developments. The company continues patient screenings at Rocky Vista University and anticipates the University of Pittsburgh Medical Center to start soon. ENDRA initiated in-person sales for its TAEUS system in Europe, supported by a growing patent portfolio of 87 global assets. Despite a net loss of $3.2 million and operating expenses rising to $3.2 million, cash reserves stand at $14 million. CEO Francois Michelon expressed optimism for FDA clearance in 2021, despite potential delays.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will report its Q2 2021 financial results on August 12, 2021, following the market close. The management will host a conference call and webcast at 4:30 p.m. ET to discuss results and recent corporate updates. The company is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at visualizing tissue at a fraction of MRI costs, particularly for assessing liver conditions like NAFLD and NASH. The technology is compatible with numerous existing ultrasound systems.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will participate in A.G.P.'s Virtual MedTech Summer Conference on July 29, 2021. This event includes 1-on-1 virtual investor meetings, allowing investors to connect with the management team. ENDRA is a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a technology that visualizes tissue at a fraction of MRI costs. TAEUS® targets chronic liver conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), affecting over one billion people globally.
ENDRA Life Sciences (NASDAQ:NDRA) has expanded its patent portfolio with three newly issued patents from the USPTO related to its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. The patents include methods for estimating liver fat content, determining material parameters, and monitoring temperature during thermal ablation. This growth in intellectual property, now totaling 86 assets, is aimed at enhancing the commercial application of TAEUS®, which targets significant medical challenges like Non-Alcoholic Fatty Liver Disease. The company emphasizes protecting its innovations in key global markets.
ENDRA Life Sciences (NASDAQ:NDRA) has appointed Irina Pestrikova as the new Senior Director of Finance and Principal Financial Officer, effective June 18, 2021. She will take over the responsibilities previously held by David Wells, who is departing to pursue another opportunity. Pestrikova has been with ENDRA since 2014, contributing to its financial planning and accounting functions. Wells will assist in the transition until September 2021.
This leadership change comes as ENDRA continues to innovate with its Thermo Acoustic Enhanced UltraSound (TAEUS) technology for liver and other clinical applications.
ENDRA Life Sciences (NASDAQ:NDRA) is set to be added to the Russell Microcap Index, effective June 28, 2021, following a preliminary announcement on June 4. The CEO, Francois Michelon, expressed enthusiasm for this milestone, highlighting its potential to enhance the company's visibility in the investment community. Membership in this index serves as a benchmark for smaller growth stocks and facilitates automatic inclusion in various growth and value style indexes, benefiting approximately $10.6 trillion in asset benchmarks.
ENDRA Life Sciences (NASDAQ:NDRA) reported its Q1 2021 financial results, revealing a net loss of $2.3 million ($0.06 per share), an improvement from a loss of $3.3 million ($0.29 per share) in Q1 2020. Operating expenses decreased to $2.6 million from $3.1 million year-over-year. The company secured a total of $12.6 million through warrant exercises and its ATM facility. Significant advancements include partnerships with Hepion Pharmaceuticals and Inselspital University Hospital for clinical validation of the TAEUS system, aimed at assessing liver conditions. Cash reserves stood at $16.8 million as of March 31, 2021.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced it will report its first quarter 2021 financial results on May 17, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and recent corporate developments. ENDRA is known for its Thermo Acoustic Enhanced UltraSound (TAEUS®), a cost-effective ultrasound technology aimed at assessing liver conditions affecting over 1 billion individuals worldwide. More information can be found on their website.
